2026 ASCO Gastrointestinal Cancers Symposium
Trials whose public commentary places their results at 2026 ASCO Gastrointestinal Cancers Symposium, Jan 8–10, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
6 trials: 0 with reports and 6 with no report yet. Organised by American Society of Clinical Oncology (ASCO); cosponsored by AGA, ASTRO and SSO; Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
No published report on a trial placed at 2026 ASCO Gastrointestinal Cancers Symposium yet.
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Colorectal cancer · 1 | |||||||
| BREAKWATER encorafenib plus cetuximab plus mFOLFOX6; encorafenib plus cetuximab placed at 2026 ASCO Gastrointestinal Cancers Symposium by 11 sources NCT04607421 · Pfizer DeepView → | first-line BRAF V600E-mutant metastatic colorectal cancer | Phase 3 | Deep | View | |||
| Gastric cancer · 1 | |||||||
| CRITICS-II docetaxel plus oxaliplatin plus capecitabine; paclitaxel plus carboplatin placed at 2026 ASCO Gastrointestinal Cancers Symposium by 2 sources NCT02931890 · The Netherlands Cancer Institute StandardView → | resectable gastric cancer | Phase 2 | Standard | View | |||
| Gastroesophageal adenocarcinoma · 2 | |||||||
| HERIZON-GEA-01 zanidatamab; zanidatamab plus tislelizumab placed at 2026 ASCO Gastrointestinal Cancers Symposium by 16 sources NCT05152147 · Jazz Pharmaceuticals DeepView → | HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma | Phase 3 | Deep | View | |||
| ILUSTRO zolbetuximab plus mFOLFOX6 plus nivolumab; zolbetuximab plus mFOLFOX6; zolbetuximab placed at 2026 ASCO Gastrointestinal Cancers Symposium by 4 sources NCT03505320 · Astellas Pharma Global Development, Inc. DeepView → | CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma | Phase 2 | Deep | View | |||
| Hepatocellular carcinoma · 2 | |||||||
| KEYNOTE-937 pembrolizumab placed at 2026 ASCO Gastrointestinal Cancers Symposium by 3 sources NCT03867084 · Merck Sharp & Dohme LLC DeepView → | hepatocellular carcinoma after surgical resection or local ablation | Phase 3 | Deep | View | |||
| CheckMate 9DW nivolumab plus ipilimumab placed at 2026 ASCO Gastrointestinal Cancers Symposium by 2 sources NCT04039607 · Bristol-Myers Squibb DeepView → | first-line unresectable hepatocellular carcinoma | Phase 3 | Deep | View | |||